about
Epimutation and cancer: a new carcinogenic mechanism of Lynch syndrome (Review)Implantation-dependent expression of trophinin by maternal fallopian tube epithelia during tubal pregnancies: possible role of human chorionic gonadotrophin on ectopic pregnancyIntermittent pneumatic compression for prevention of pulmonary thromboembolism after gynecologic surgeryMicroRNAS in endometrial cancer: recent advances and potential clinical applicationsMicroRNA in cervical cancer: OncomiRs and tumor suppressor miRs in diagnosis and treatmentIndocyanine green fluorescence imaging for evaluation of uterine blood flow in cynomolgus macaqueOverexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinomaAssociation of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cellsA genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in JapaneseLATS1/WARTS phosphorylates MYPT1 to counteract PLK1 and regulate mammalian mitotic progressionTrophoblast cell activation by trophinin ligation is implicated in human embryo implantationEstablishment and characterization of the RMG-V cell line from human ovarian clear cell adenocarcinoma.A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma.A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer.Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.Comparison Between Laparoscopy and Laparotomy in Systematic Para-Aortic Lymphadenectomy for Patients with Endometrial Cancer: A Retrospective Multicenter Study.Trends in gynecologic cancer mortality in East Asian regions.Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).Features of ovarian cancer in Lynch syndrome (Review).The origin of stroma surrounding epithelial ovarian cancer cells.Up-regulation of Imp3 confers in vivo tumorigenicity on murine osteosarcoma cells.Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.A novel method for analyzing formalin-fixed paraffin embedded (FFPE) tissue sections by mass spectrometry imaging.Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome.LATS1 and LATS2 phosphorylate CDC26 to modulate assembly of the tetratricopeptide repeat subcomplex of APC/C.Establishment of a choriocarcinoma model from immortalized normal extravillous trophoblast cells transduced with HRASV12Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer.Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancerHigh Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer.Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer.A new surgical technique of uterine auto-transplantation in cynomolgus monkey: preliminary report about two cases.Identification of mono- and disulfated N-acetyl-lactosaminyl Oligosaccharide structures as epitopes specifically recognized by humanized monoclonal antibody HMOCC-1 raised against ovarian cancer.Endometrial Cancer and Hypermethylation: Regulation of DNA and MicroRNA by EpigeneticsAssociation of HNPCC and endometrial cancers.Anisakiasis mimics cancer recurrence: two cases of extragastrointestinal anisakiasis suspected to be recurrence of gynecological cancer on PET-CT and molecular biological investigation.
P50
Q22255392-EE879581-C9CF-494E-90FA-0976204524B0Q24672425-3F5E06A8-C218-4A13-A47E-B83B95B74E04Q24815921-18C9DC37-6466-4525-896F-4B032E969A3CQ26780358-0EDE307F-892C-43A9-A10A-48686575839EQ27011808-715E829B-F5A7-47FA-96F1-E5C3F70FCEDEQ27304692-5F03FD67-815A-4521-972A-3D90C225DEE9Q28235707-EC8DD04D-A657-4F5D-9724-37AD8E758F8BQ28271164-B56A4EC7-49FB-41FC-A8C2-12BE5B1C0A1FQ28286993-EAC91DE8-1DA9-4511-958F-5E9029F2819BQ30522305-7E1A38F0-F7B4-4E79-9AC4-F49DC29181B9Q33278668-9A2D6740-05BB-47D6-9F64-E7AEE9FDEE9CQ33343234-8536D641-ED8A-48C2-97B2-5E08E1A45BDFQ33392451-F95CB94F-59C9-4ED2-A12E-E04139604603Q33415973-35CF4C53-E8CF-418B-9D74-8E0F481B0DDCQ33420283-A4C04F3E-4A31-4842-A0D9-7B9A57D7AF81Q33431951-01836A13-E73B-4272-B1FF-4067E94CA42CQ33433804-285A66EC-5CBF-4040-A1A0-A8CD6C9CF1EAQ33598001-6CFAF9E6-C6D7-4680-A85A-E4505BBB1318Q33600629-C095F880-13AA-47F7-B5FD-3AE5A095D7D3Q33647706-971E9AD6-89EC-473D-8EFB-F53D56FFEAB6Q33782863-DAA14C51-0A7E-426E-8ED1-AD832C40712EQ33917307-4CBEA17A-A2E9-4EAA-8F4B-EF431B3C8162Q33933054-47B17283-1EF9-42DB-BF75-36E27B521999Q34265940-BA90448E-B5D4-4A9D-BE1B-923E67F11F60Q34497791-F9DDF3C0-D9DA-4972-BC18-47AEE204DCEBQ34505648-9F6607E7-822F-4487-9850-7186D8A91240Q35039169-A87F43F3-A5E2-4E09-87E1-2730E223E751Q35075069-AD045A29-A46E-4A29-86F5-4C40B34D35B7Q35084724-265E597B-499E-4EF6-ACBF-4D7DC2A9A4B5Q35130113-72846717-62C2-40ED-9FB8-38ADFE393300Q35167913-C061045A-C064-42F4-A0B2-D32ED0BEA215Q35168142-35A0A0C8-8524-408B-85C9-0EF96B640CD0Q35179515-4E05CE12-BD64-4430-827C-1EEF09BB78E1Q35288939-713C61C5-12B0-410A-8071-FAB770739523Q35607535-A131FC16-BD54-45DC-A4BD-568F9C980433Q35644089-DF6085B7-3879-46DD-AFA1-08F10D1A574AQ35839005-08DB22D0-091C-46F8-B8A0-A5FB790CFBDDQ35882785-1883F814-F1B7-4D2A-8A16-3384AA7D0215Q35891110-DABD0586-341B-445E-AC7B-477933FD7FBFQ35998758-8E37FABD-EC3F-401D-AD6E-A50E535319A1
P50
description
researcher (ORCID 0000-0002-9596-8326)
@en
name
Daisuke Aoki
@en
type
label
Daisuke Aoki
@en
prefLabel
Daisuke Aoki
@en
P31
P496
0000-0002-9596-8326